Hao Qiang, Wei Dong, Zhang Yaoguang, Chen Xin, Yang Fan, Yang Ze, Zhu Xiaoquan, Wang Jianye
Graduate School of Peking Union Medical College, Beijing, 100730, China.
Department of Urology, Beijing Hospital, Beijing, 100730, China.
Oncotarget. 2016 Apr 19;7(16):22271-84. doi: 10.18632/oncotarget.7926.
In the past twenty-five years, over 700 case-control association studies on the risk of prostate cancer have been published worldwide, but their results were largely inconsistent. To facilitate following and explaining these findings, we performed a systematic meta-analysis using allelic contrasts for gene-specific SNVs from at least three independent population-based case-control studies, which were published in the field of prostate cancer between August 1, 1990 and August 1, 2015. Across 66 meta-analyses, a total of 20 genetic variants involving 584,100 subjects in 19 different genes (KLK3, IGFBP3, ESR1, SOD2, CAT, CYP1B1, VDR, RFX6, HNF1B, SRD5A2, FGFR4, LEP, HOXB13, FAS, FOXP4, SLC22A3, LMTK2, EHBP1 and MSMB) exhibited significant association with prostate cancer. The average summary OR was 1.33 (ranging from: 1.016-3.788) for risk alleles and 0.838 (ranging from: 0.757-0.896) for protective alleles. Of these positive variants, FOXP4 rs1983891, LMTK2 rs6465657 and RFX6 rs339331 had not been previously meta-analyzed. Further analyses with sufficient power design and investigations of the potential biological roles of these genetic variants in prostate cancer should be conducted.
在过去25年里,全球发表了700多项关于前列腺癌风险的病例对照关联研究,但其结果大多不一致。为便于追踪和解释这些发现,我们进行了一项系统的荟萃分析,使用等位基因对比分析至少三项基于人群的独立病例对照研究中特定基因单核苷酸变异(SNV),这些研究发表于1990年8月1日至2015年8月1日的前列腺癌领域。在66项荟萃分析中,共有涉及19个不同基因(KLK3、IGFBP3、ESR1、SOD2、CAT、CYP1B1、VDR、RFX6、HNF1B、SRD5A2、FGFR4、LEP、HOXB13、FAS、FOXP4、SLC22A3、LMTK2、EHBP1和MSMB)的20种基因变异与前列腺癌显著相关。风险等位基因的平均汇总比值比为1.33(范围:1.016 - 3.788),保护性等位基因的平均汇总比值比为0.838(范围:0.757 - 0.896)。在这些阳性变异中,FOXP4 rs1983891、LMTK2 rs6465657和RFX6 rs339331此前未进行过荟萃分析。应进行有足够效力设计的进一步分析,并研究这些基因变异在前列腺癌中的潜在生物学作用。